Status:
COMPLETED
Limitations of Aerobic Capacity in Chronic Heart Failure
Lead Sponsor:
University of Leeds
Conditions:
Chronic Heart Failure
Eligibility:
All Genders
Phase:
NA
Brief Summary
This study will use a novel CPX test that incorporates instantaneous assessment of maximal isokinetic cycling power at V̇O2peak to elucidate the mechanisms that limit V̇O2peak in CHF, and compare thes...
Detailed Description
Chronic heart failure (CHF) is a current and growing public health concern that is expensive to treat (annual costs account for approximately 1.8% of the National Health Service budget), and associate...
Eligibility Criteria
Inclusion
- Patients with NYHA class I-III
- Stable CHF of at least 3 months duration
- On optimally tolerated medication for CHF
- No contraindications for cycling exercise
- Able to give informed consent
Exclusion
- Class IV CHF
- Any contraindications to exercise
- Co-morbidities: significant COPD (FEV1\<50%), severe renal disease (eGFR\<20) or primary pulmonary hypertension as a co-morbidity
- Unable to give informed consent
- Current diagnosis of cancer, inflammatory or musculoskeletal disease (e.g. rheumatoid arthritis), on-going infection or sepsis.
Key Trial Info
Start Date :
December 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 18 2024
Estimated Enrollment :
91 Patients enrolled
Trial Details
Trial ID
NCT04332536
Start Date
December 1 2019
End Date
October 18 2024
Last Update
October 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Leeds Teaching Hospitals NHS Trust
Leeds, West Yorkshire, United Kingdom, LS16 5AR